NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Bluebird bio Inc. ("Bluebird" or the "Company") (NASDAQ:BLUE) on behalf of Bluebird stockholders. Our investigation concerns whether Bluebird has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On March 26, 2024, before the market opened, bluebird filed an 8-K with the SEC in which it announced, "[o]n March 24, 2024, the Audit Committee of the Board of Directors (the 'Audit Committee') of the Company, based on the recommendation of management and after ...